Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen/Nasdaq New York: ZEAL) (Copenhagen, Denmark) is a biotechnology company with leading expertise in the discovery, design and development of novel peptide medicines, in-house competences in clinical trial design and management and a therapeutic focus on cardio-metabolic diseases. The company has a broad portfolio of therapeutic products – proprietary and partnered.
Company pipeline includes four product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon, formulated for use in a single-dose, ready-to-use disposable injection pen, which is being developed as a rescue treatment for severe hypoglycemia or ‘‘insulin shock’’; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism.
For more information, please contact:
Phone: +45 4080 4869